Nanopharmaceuticals

European Journal of Nanomedicine

Volumn 3, Issue 1, 2010, Pages 34-40

  Bawa, Raj ^a,b,c,d  

^a Bawa Biotechnology Consulting LLC   (United States)

^b RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^c SynerGene Therapeutics Inc   (United States)

^d American Society for Nanomedicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE AGENTS; BIOLOGICAL TARGETS; BROAD SPECTRUM; CLINICAL TRIAL; DRUG FORMULATIONS; DRUG METABOLISMS; ECONOMIC LIFE; HIGH SURFACE-TO-VOLUME RATIO; IMMUNOGENICITY; INTEGRAL PART; INTRACELLULAR DELIVERY; NANO-MATERIALS; NANOMEDICINES; NANOPHARMACEUTICALS; PATIENT COMPLIANCE; PHARMACEUTICAL INDUSTRY; PHYSIO-CHEMICAL PROPERTIES; REVENUE STREAMS; SINGLE MOLECULE; SMALL SIZE; SPECIFIC SITES; THERAPEUTIC AGENTS; THERAPEUTIC APPLICATION; US FOOD AND DRUG ADMINISTRATION;

BIOCHEMISTRY; DRUG PRODUCTS; MEDICAL NANOTECHNOLOGY; NUCLEIC ACIDS; TISSUE;

HEALTH CARE;

NANOMATERIAL;

DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG INDUSTRY; DRUG METABOLISM; HUMAN; NANOMEDICINE; NANOPHARMACEUTICS; NANOTECHNOLOGY; NONHUMAN; PHARMACODYNAMICS; REVIEW;

EID: 79953796430     PISSN: 16625986     EISSN: 1662596X     Source Type: Journal    
DOI: 10.3884/0003.1.9     Document Type: Review

References (43)

1. Reisner DE. (editor). Bionanotechnology: Global Prospects. CRC Press, 2009; Boca Raton, FL.
2. Hornyak GL, Dutta J, Tibbals HF, Rao AK. (editors). Introduction to Nanoscience. CRC Press, 2008; Boca Raton, FL.
3. Van Lente, MA. Building the new world of nanotechnology. Case W. Res. J. Int. Law 2006; 38(1): 173-215.
4. Edwards SA. 2006. The Nanotech Pioneers - Where Are They Taking US? Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany.
5. Vo-Dinh T, (editor). Nanotechnology in Biology and Medicine: Methods, Devices, and Applications CRC Press, 2007; Boca Raton, FL
6. Report: NANOtechnology: Untold promise, unknown risk. Consum. Reports 2007; 72(7): 40-45.
7. National Science Foundation: Societal Implications of Nanoscience and Nanotechnology. Arlington, VA: National Science Foundation; 2001, 272.
8. Bawa R. Special Report - Patents and nanomedicine. Nanomedicine 2007; 2(3): 351-374.
9. Bawa R. Patenting inventions in bionanotechnology: A primer for scientists and lawyers. In: D. E. Reisner (editor). Bionanotechnology: Global Prospects. CRC Press, 2009; Boca Raton, FL 309-337.
10. The National Nanotechnology Initiative. http://www.nano.gov/html/facts/ whatIsNano.html. [Last visited November 20, 2009]
11. European Science Foundation. Nanomedicine - An ESF-European Medical Research Councils (EMRC) forward look report. 2004; Strasbourg cedex, France.
12. Bawa R, et al. Nanopharmaceuticals - patenting issues and FDA regulatory challenges. American Bar Association SciTech Lawyer 2008; 5(2): 10-15.
13. Bawa R. Nanoparticle-based therapeutics in humans: a survey. Nanotechnology Law & Business 2008; 5(2): 135-155.
14. Pommier Y. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle check points. Curr Med Chem Anticancer Agents 2004; 4: 429-434.
15. Popielarski SR, Hu-Lieskovan S, French SW, Triche TJ, Davis MEA. Nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 2. In vitro and in vivo uptake results. Bioconjug Chem 2005; 16: 1071-1080. (Pubitemid 41368107)
16. Davis ME. Nanoparticles for systemic medicines and imaging agents. Nanotechnology Law & Business 2006; 3(3): 255-261. (Pubitemid 44618218)
17. Harris JM, Chess RB. Effect of peglyation on pharmaceuticals. Nat Rev Drug Discovery 2003; 2: 214-221.
18. Breunig M et al. Polymers and nanoparticles: intelligent tools for intracellular targeting? Eur J Pharm Biopharm 2008; 68: 112-128.
19. Tosi G et al. Polymeric Nanoparticles for the Drug Delivery to the Central Nervous System. Expert Opinion on Drug Delivery 2008; 5: 155.
20. Zhang Y et al. Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer. Mol Vis 2003; 9: 465-472. (Pubitemid 38097614)
21. Emerich DF, Thanos CG. The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis. Biomolecular Engineering 2006; 23: 171-184. (Pubitemid 44142336)
22. Matsumura Y, Maeda H. A new concept of macromolecular therapies in cancer chemotherapy: mechanism of tumortropic accumulation of proteins and the antitumor agent SMANCS. Cancer Research 1986; 6: 6387-6392. (Pubitemid 17221789)
23. Blanco MD, Alonso MJ. Development and characterization of protein-loaded poly-lactide-coglycolide nanosphers. Eur J Pharm Biophar 1997; 43: 287-294.
24. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discovery 2004; 3(9): 785-796. (Pubitemid 39242830)
25. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmaco 2004; 56(7): 827-840. (Pubitemid 38885975)
26. Lipinski C. Poor aqueous solubility: an industry wide problem in drug discovery. Am Pharm Rev 2002; 5: 82-85.
27. Radtke M. Pure drug nanoparticles for the formulation of poorly soluble drugs. New Drugs 2001; 3: 62-68.
28. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001; 47(1): 3-19. (Pubitemid 32209229)
29. Liversidge EM, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly water-soluble compounds. Eur J Pharm Sci 2003; 18(2): 113-120. (Pubitemid 36184748)
30. Junghanns J-U, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed 2008; 3(3): 295-309.
31. Liversidge GG et al. Surface Modified Drug Nanoparticles. 1992; US Patent No. 5,145,684.
32. Liversidge GG, Cundy CC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. absolute oral bioavailability of nanocrystalline Danazol in beagle dogs. Int J Pharm 1995; 125(1):91-97.
33. Liversidge GG, Conzentino P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm 1995; 125(2): 309-313.
34. Liversidge EM et al. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res 1996; 13(2): 272-278.
35. Bawa R. Patenting inventions in nanomedicine: a catalyst for commercialization? Small Times 2005; 5(8): 16.
36. Bawa R. Will the nanomedicine "patent land grab" thwart commercialization? Nanomedicine: NBM 2005; 1: 346-350.
37. O'Neill S, Hermann K, Klein M, Bawa, R. et al. Broad claiming in nanotechnology patents: is litigation inevitable? Nanotechnology Law and Business 2007; 4(1): 595-606.
38. Harris D, Bawa R. The carbon nanotube patent landscape in nanomedicine: an expert opinion. Expert Opinion on Therapeutic Patents 2007; 17(9): 1165-1174.
39. McKinnie J. Nanobiotechnology offers a promising solution overcoming common drug delivery failures. Drug Delivery Technology 2006; 5: 11-15.
40. Hess G. Congress divided on patent reform. Chemical & Engineering News 2009; 87(20): 34-35.
41. Jaffe AB, Lerner J. Patent prescription: a radical cure for the ailing US patent system. IEEE Spectrum 2005; 42: 38-43.
42. Shapiro C. Patent system reform: economic analysis and critique. Berkeley Technology Law Journal 2004; 19: 1017-1019.
43. Fender J. The FDA and Nano: Big Problems with Tiny Technology. Chi-Kent L Rev 2008; 83: 1063.